Fluoguide AS

FLUO · Nasdaq Stockholm · Healthcare

35.00SEK +3.2%last day

Price as of 2 October 2026

The price over the past year, with dividends: −10.7%

Performance

1 month

−3.0%

1 year

−10.7%

3 years, per year

−25.0%

5 years, per year

−17.7%

Largest fall, 3 years

−73.6%

Below the peak now

−77.9%

Volatility, 1 year

57.0%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

12.1

Dividend yield

0.0%

Return on equity

−150.4%

Net margin

–

Market value

57 m USD

Quality, value and trend

Where Fluoguide stands against every Nordic stock today. 100 is best.

Quality47

Profitability and a sound balance sheet over time. Better than 47% of Nordic stocks.

Value2

The price measured against earnings, assets and cash flow. Better than 2% of Nordic stocks.

Trend30

The price development over the past year. Better than 30% of Nordic stocks.

Combined9

Quality, value and trend together. Better than 9% of Nordic stocks.

About Fluoguide

Fluoguide AS is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 6 employees.

FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis